Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellegy Pharmaceuticals expects to discover whether it can market Cellegesic, a drug designed to treat pain associated with chronic anal fissure, by June 15, 2005. The review date set by the FDA was announced in a recent letter to the company.
Subscribe to our email newsletter
Following notice given in December 2004 that the FDA would not approve the product for release after the company’s first submission, Cellegy has provided a written response containing new analyses of data from its three Cellegesic phase III trials.
The FDA has indicated that under the agency’s procedural rules, Cellegy’s reply is being viewed as a “complete, Class 1” response to their initial rejection letter. A “Class 1 resubmission” is a resubmission that includes a minor re-analysis of data previously submitted to the application.
Cellegesic (0.4% nitroglycerin ointment), is already approved outside the US under the name Rectogesic for the treatment of pain associated with chronic anal fissures. Launch of Rectogesic in the UK is expected in the first half of 2005. A similar formulation of Rectogesic is currently being sold in Australia, New Zealand, Singapore and South Korea.